신약 이름 정리

Enhertu 엔허투, Trastuzumab deruxtecan,  HER2-positive breast cancer 

  antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to     the topoisomerase I inhibitor deruxtecan (a derivative of exatecan)

  https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan

  https://www.medifonews.com/news/article.html?no=190962 

 엔허투, HER2 저발현 전이성 유방암‧HER2 변이 전이성 비소세포폐암에 허가

 

Erbitux얼비툭스, Cetuximab, 직장암 약

  https://en.wikipedia.org/wiki/Cetuximab

  ‘얼비툭스’ 비소세포폐암 생존기간 늘려

  https://www.docdocdoc.co.kr/news/articleView.html?idxno=65860

 

ORIC-114

ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, making it a promising therapeutic candidate to address the unmet medical need of having both meaningful systemic as well as CNS antitumor activity.

https://investors.oricpharma.com/news-releases/news-release-details/initial-phase-1-dose-escalation-data-oric-114-patients-egfr-and

 

Rybrevant 리브리반트, Amivantamab

  Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and MET receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

  https://en.wikipedia.org/wiki/Amivantamab

   https://www.rybrevant.com/

https://www.docdocdoc.co.kr/news/articleView.html?idxno=3014933 

    ‘리브리반트’, EGFR 엑손20 변이 폐암 1차 치료제 등극

  https://www.monews.co.kr/news/articleView.html?idxno=334848

FDA, 타그리소 치료 실패 폐암 환자에 '리브리반트+화학요법' 허가

 

Trodelvy트레델비 ,Sacituzumab govitecan, by Gilead Sciences 삼중음성유방암 약

  https://en.wikipedia.org/wiki/Sacituzumab_govitecan

길리어드 '트로델비' 비소세포폐암 환자 OS 연장 '실패'(2024.1.23.)

길리어드에 따르면 트로델비는 도세탁셀에 비해 OS에서 수치적으로 개선이 관찰됐지만, 1차 목표점을 충족하지는 못했다.

 https://www.monews.co.kr/news/articleView.html?idxno=329444